{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:06 23:25:58.836",
            "Expression": "mesenchymal SMUP-IA-01",
            "NStudiesAvail": 430108,
            "NStudiesFound": 3,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 3,
            "FieldList": [
                  "DesignTimePerspective",
                  "DesignWhoMasked",
                  "DetailedDescription",
                  "DispFirstPostDate",
                  "DispFirstPostDateType",
                  "DispFirstSubmitDate",
                  "DispFirstSubmitQCDate",
                  "EligibilityCriteria",
                  "EnrollmentCount",
                  "EnrollmentType",
                  "EventGroupDeathsNumAffected",
                  "EventGroupDeathsNumAtRisk",
                  "EventGroupDescription",
                  "EventGroupId",
                  "EventGroupOtherNumAffected",
                  "NCTId"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "DesignTimePerspective": [],
                        "DesignWhoMasked": [],
                        "DetailedDescription": [
                              "The subjects will be followed up at 6-month, 12-month, 24-month, 36-month, 48-month and 60-month after the initial administration of SMUP-IA-01."
                        ],
                        "DispFirstPostDate": [],
                        "DispFirstPostDateType": [],
                        "DispFirstSubmitDate": [],
                        "DispFirstSubmitQCDate": [],
                        "EligibilityCriteria": [
                              "Inclusion Criteria:\n\nSubject who completed the safety and explore efficacy evaluations in SMUP-IA-01 Phase I clinical trial.\nSubjects who have been treated with either SMUP-IA-01 at least 6 months ago.\nSubjects who voluntarily decided to participate and signed the consent form after receiving explanations on the clinical trial.\n\nExclusion Criteria:\n\nSubjects who were not enrolled in phase 1 clinical trial of SMUP-IA-01 for assessing safety and explore efficacy.\nOther subjects, excluding those listed above, who were deemed unsuitable by the PI"
                        ],
                        "EnrollmentCount": [
                              "12"
                        ],
                        "EnrollmentType": [
                              "Anticipated"
                        ],
                        "EventGroupDeathsNumAffected": [],
                        "EventGroupDeathsNumAtRisk": [],
                        "EventGroupDescription": [],
                        "EventGroupId": [],
                        "EventGroupOtherNumAffected": [],
                        "NCTId": [
                              "NCT04339504"
                        ]
                  },
                  {
                        "Rank": 2,
                        "DesignTimePerspective": [],
                        "DesignWhoMasked": [],
                        "DetailedDescription": [
                              "All subjects in each dose-group will visit 1 month* (visit 5, 1 month\u00b15 days) after administration of investigational product to evaluate dose limit toxicity (DLT) and determine whether to drop or proceed to next dose level.\n\nTotal 5 visit (1week, 1 month, 2 months, 3 months, 6 months) until 6 months after administration of investigational product is planned to assess safety through vial sign, laboratory tests, and exploratory efficacy of IP will be assessed through Western Ontario and McMaster Universities osteoarthritis index (WOMAC), 100-mm visual analogue scale (VAS) and International Knee Documentation Committee (IKDC) subjective knee evaluation."
                        ],
                        "DispFirstPostDate": [],
                        "DispFirstPostDateType": [],
                        "DispFirstSubmitDate": [],
                        "DispFirstSubmitQCDate": [],
                        "EligibilityCriteria": [
                              "Inclusion Criteria:\n\nMale and female over 19 years of age\nSubject with knee osteoarthritis (OA) and were diagnosed K&L grade 2 or 3 in radioactive examination at time of screening\nSubject with more than 40mm joint pain on the 100-mm VAS, at the time of screening\nSubject who were diagnosed as knee osteoarthritis by American College of Rheumatology (ACR) guideline criteria, at the time of screening\nSubject with Body mass index (BMI) \u226435 kg/m2 at the time of screening\nSubject with ligament instability \u2264Grade II (grade o: no ligament instability, grade I: 0 ~ 5\u339c, grade \u2161: 5 ~ 10 \u339c, grade \u2162: > 10 \u339c) at the time of screening\nSubject who agree to maintain contraception during study period\nSubject who voluntarily agreed to participate in the study, and signed informed consent\n\nExclusion Criteria:\n\nSubject with myocardial infarction, congestive heart failure, and other severe heart disease or hypertension (or medical history of hypertension) that are not controlled below 140/90mmHg even with treatment with more than three(3) antihypertensive drugs\nSubject with serious medical conditions other than cardiovascular disease\nSubject with, or with a medical history of auto-immune diseases\nSubject with an infection that requires parenteral antibiotic administration.\nSubject with a medical history of mental disorder or epilepsy\nSubject with chronic inflammatory joint diseases such as rheumatoid arthritis (e.g., osteoarthritis with infectious joint disease, gouty arthritis, and osteoarthritis)\nSubject who had surgery or radiation therapy on knee joint area, or have not recovered from side effects of knee joint surgery within 12 weeks before screening\nSubject who are pregnant or lactating\nSubject abuse alcohol 10 times a week or smoke 25 cigarettes a day\nSubject who were diagnosed with cancer within 5 years before screening\nSubject who particiapted in another clinical trial within 4 weeks before screening of this clinical trial\nSubject who were administered with immunosuppressnats such as cyclosporin A or azathioprine within 6 weeks before screening\nSubject who had intra-articular administration such as sodium hyaluronate injections within 6 month before screening\nSubject who are suffering from skin disease or considered inappropriate for injection in the injection site\nSubject who has history of allergic response to hyaluronate injections or DMSO (cryopreservative) or Gentamicin (antibiotics)\nSubject who are consiered inappropriate for MRI assessment with Tesla higher than 3.0\nSubject with medical history of cell therapy product administration or are scheduled to administer other cell therapy product\nSubject who principal investigator (PI) considers inappropriate to participate in the study due to any reasons other than those listed above"
                        ],
                        "EnrollmentCount": [
                              "12"
                        ],
                        "EnrollmentType": [
                              "Actual"
                        ],
                        "EventGroupDeathsNumAffected": [],
                        "EventGroupDeathsNumAtRisk": [],
                        "EventGroupDescription": [],
                        "EventGroupId": [],
                        "EventGroupOtherNumAffected": [],
                        "NCTId": [
                              "NCT04037345"
                        ]
                  },
                  {
                        "Rank": 3,
                        "DesignTimePerspective": [],
                        "DesignWhoMasked": [
                              "Participant",
                              "Investigator"
                        ],
                        "DetailedDescription": [
                              "Patients who meet the inclusion/exclusion criteria will be randomly assigned at visit 2 to either of study group 1(low-dose), study group 2 (mid-dose) or active control group at 1:1:1 ratio. Patients will be administered with investigational product. Investigational product will be administered into the to-be-treated (index) knee one time within 7 days after randomization.\n\nAll patients enrolled will be followed up a total of 6 times (1, 4, 8, 12, 24, and 52 weeks) for up to post-dose 12 months. The patients should visit the study facility according to the visit schedule, and will undergo safety evaluation (vital sign, laboratory test, etc.) and efficacy evaluation [Western Ontario and McMaster Universities osteoarthritis index (WOMAC), 100-mm visual analogue scale (VAS), International Knee Documentation Committee (IKDC) subjective knee evaluation]."
                        ],
                        "DispFirstPostDate": [],
                        "DispFirstPostDateType": [],
                        "DispFirstSubmitDate": [],
                        "DispFirstSubmitQCDate": [],
                        "EligibilityCriteria": [
                              "Inclusion Criteria:\n\nPatients who are \u2265 19 years of age on the date on which the consent form was signed\nPatients diagnosed with knee osteoarthritis in at least one knee according to the clinical and radiological definition criteria of American College of Rheumatology (ACR) guidline at screening visit\nPatients with knee OA corresponding to K&L Grade 2 or 3 on radiographic examination at screening visit\nPatients with less than 35 of BMI at screening visit\nPatients who voluntarily decide to participate and sign the consent form\nPatients who have persistent symptoms despite having undergone a reasonable trial of standard therapy (i.e., for a minimum of 3 months)\n\nExclusion Criteria:\n\nPatients with any of the following diseases.\n\n- infectious arthritis, autoimmune or inflammatory joint diseases, gout, recurrent pseudogout, Paget's disease, intra-articular displaced fracture, ochronosis, acromegaly, haemochromatosis, Wilson's disease, genetic disease (hyperkinesia etc.), genetic collagen disorder, etc.\n\nPatients who have ever undergone surgery or radiotherapy in the knee joint area within the 12 weeks prior to the screening visit date, or who have not been recovered from its side effect yet.\nPatients with SIF (Subchondral insufficiency fracture) corresponding to type II of the RPOA (rapidly progressive osteoarthritis).\nPatients whose physical examination results show severe degree of ligament instability.\nPatients who have ever been given any intraarticular drug injection (i.e., hyaluronic acid injection, etc.) in to-be-treated (index) knee within the 6 months, prior to the screening visit date.\nPatients who have ever been given steroids via intraarticular injection in to-be-treated (index) knee within the 12 weeks prior to the screening visit date.\n\nPatients who have ever taken medications or given therapy below within the past 2 weeks on the basis of screening visit date. However, if patients have 14 days of wash-out period, the patient is allowed to participate.\n\ndrugs containing the ingredient of glucosamine, chondroitin sulfate, or diacerein\ndrugs containing herbal ingredient or herbal drugs for knee OA pain relief\nanti-inflammatory analgesics or NSAIDs (prescription/non-prescription drugs). (However, patients who take acetaminophen and have 3 days of wash-out period are allowed to participate.)\noral steroids\nhospital physiotherpy or oriental medicine treatment (buhang, acupunture, moxibustion etc.)\nPatients who have skin disease on injection site or who are judged inappropriate for intra-articular injection on to-be-treated knee.\nPatients who are judged unsuitable for MRI scanning (3.0 Tesla or higher) due to an insertion of metal material (i.e., heart pacemaker, cerebral aneurysm clip, etc.) or obstructive phobia. However, patients who have an insertion of metal material that is not affected by the magnetic field is allowed to participate\n\nPatients with clinically significant past or present illness as follows;\n\nheart diseases (i.e., myocardial infarction, coronary artery bypass surgery, arrhythmia and other serious heart diseases, etc.)\nuncontrolled hypertension (not controlled down to 140/90 mmHg or below even after treatment with 3 or more antihypertensive drugs)\nkidney disease (i.e., chronic kidney failure, glomerulonephritis, etc.)\nliver disease (i.e., acute or chronic liver disease such as cirrhosis, fatty liver, etc.)\nendocrine diseases (i.e., thyroiditis, diabetes insipidus, Cushing's disease, etc.)\nother serious systemic diseases\nPatient with ongoing autoimmune disorder that requires treatment with an immunosuppressive medication\nPatients with infection that requires administration of parenteral antibiotics\nPatients with a history of mental illness or epilepsy\nPatients who have been diagnosed with cancer within the 5 years prior to the screening visit date\nPatients who have been given immunosuppressive drugs such as cyclosporin A or azathioprine within the 6 weeks prior to the screening visit\nPatients with a history of allergic reactions to hyaluronic acid injections, cryoprotectant (dimethyl sulfoxide, DMSO), or gentamicin.\nPatients who are pregnant or lactating, or patients who have a plan to become pregnant during the study period\nMale or female patients who do not agree to avoid pregnancy or the use of appropriate contraceptive methods during the study period. But women who have given infertility surgery or who have passed menopause one year or more are allowed to participate without the consent for contraception.\nPatients who have been given any other cell therapy products or who plan to do so during the study period.\nPatients who have been given any other investigational products including device within the 3 months prior to the screening visit date.\nPatients who are judged by the investigator as inappropriate for enrollment into the study, for any reasons other than the reasons specified above."
                        ],
                        "EnrollmentCount": [
                              "90"
                        ],
                        "EnrollmentType": [
                              "Anticipated"
                        ],
                        "EventGroupDeathsNumAffected": [],
                        "EventGroupDeathsNumAtRisk": [],
                        "EventGroupDescription": [],
                        "EventGroupId": [],
                        "EventGroupOtherNumAffected": [],
                        "NCTId": [
                              "NCT05182034"
                        ]
                  }
            ]
      }
}